title: [Collecting duct renal cell carcinoma].
abstract: BACKGROUND
  Bellini's renal cell collecting duct carcinoma is a rarely prevalent renal tumour, with low cancer-specific survival, although its rate of response to antiangiogenic therapies is unknown.
  
  
  OBJECTIVE
  We retrospectively revise a series of collecting duct tumours, with special emphasis on the indication of target therapies and on their results.
  
  
  METHODS
  Retrospective analysis of renal cell collecting duct carcinoma treated at our institution from January 2000 to June 2010, taking into account the patient's age, sex, reason for the consultation, oncological background, side of the affection, surgical treatment, other anatomopathological characteristics, tumour size, TNM clinical staging (2009), adjuvant treatment and survival time.
  
  
  RESULTS
  Six patients are described, five men and one woman, with a mean age of 75 (± 7.7) years. Four of them (66.6%) presented disseminated disease upon diagnosis. Five (83%) were treated with radical nephrectomy and three (50%) received systemic adjuvant treatment, without response. The means survival was 5.5 months (4.75-14.75). Only 2 patients (33.3%), both with localized disease upon diagnosis, are in complete remission.
  
  
  CONCLUSIONS
  Renal cell collecting duct carcinoma is a disease with a bad prognosis, little survival and bad response to target therapies.
authors: Servicio de Urología, Hospital General Universitario Gregorio Marañón, Madrid, España. adrhusillos@hotmail.com
authors: A
authors: A
authors: Husillos
authors: F
authors: F
authors: Herranz-Amo
authors: D
authors: D
authors: Subirá
authors: E
authors: E
authors: Lledó
authors: R
authors: R
authors: Molina-Escudero
authors: C
authors: C
authors: Hernández-Fernández
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000453:epidemiology* / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D033162:Incidental Findings; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000453:epidemiology* / Q000473:pathology / Q000601:surgery; D007685:Kidney Tubules, Collecting / Q000473:pathology*; D008297:Male; D009367:Neoplasm Staging; D009392:Nephrectomy; D011379:Prognosis; D012189:Retrospective Studies; D020123:Sirolimus / Q000031:analogs & derivatives / Q000627:therapeutic use; D016019:Survival Analysis; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; C401859:temsirolimus; D002945:Cisplatin; D020123:Sirolimus; D000093542:Gemcitabine